Richmond Pharmacology Gene editing and silencing seminar

Cutting-edge Technology powered by Magoneko series 2025 #3

Advancing in vivo gene editing and gene silencing medicines
~ Clinical Trial Insights from Rare and Prevalent Diseases in the UK ~

We are pleased to announce that we will be holding a seminar event to provide the latest information on the UK, a world leader in the fields of gene editing and gene therapy, as well as to discuss international collaboration between Japan and the UK in gene therapy.

This seminar will bring together representatives from the UK regulatory body (MHRA), healthcare facilities (NHS), clinical trial organization (Richmond Pharmacology), and the UK government organization Cell & Gene Catapult, which supports gene therapy development, to introduce the UK's world-leading clinical trials of in vivo gene editing therapy, along with the latest case studies.

This seminar is designed to provide Japanese pharmaceutical and biotechnology companies with practical hints to answer the question "Why the UK now?", including the regulatory advantages of conducting clinical trials in the UK, flexibility in patient recruitment, and societal acceptance of advanced medical treatments.

Outline

[Date/Time] Wednesday, June 4, 2025, 14:30 ~ 18:00 (Registration begins at 13:30)
[Venue] Nihonbashi Lifescience HUB Conference room A
[Address] Nihonbashi Muromachi Chibagin Mitsui bldg. 8th floor, 1-5-5 Nihonbashi Muromachi, Chuo-ku, Tokyo
[Map] Click to open Google Map
[Capacity] 100 people
[Format] On-site only (no webinar)
[Participation fee] Free
[Registration] Click to register (connect to Peatix site, you need a Peatix account)
[Application Deadline] Friday, May 30, 2025, 18:00 (Japan time. Applications will close when the capacity is reached)
[Organizer] Richmond Pharmacology Limited
[Co-organize] Magoneko Solutions Co., Ltd.
[Cooperation] British Embassy in Japan, MHRA, CGT Catapult, AMED, PMDA (in no particular order)

Program

1. Current status of gene therapy research funding in Japan
2. Gene editing in the UK: Latest scientific and infrastructure trends
3. UK advantages for accelerating clinical development
4. Regulatory trends: MHRA-supported gene editing clinical trials
5. Panel discussion: Regulatory and operational challenges and solutions for UK clinical trials
6. Business case: Benefits for Japanese companies to conduct clinical trials in the UK
7. Networking reception and one-on-one interviews